Now, the Danish pharmaceutical firm Lundbeck's operational guidance for 2020 is at DKK 1.7-1.9bn (USD 275.6m-308.0m), down from DKK 2.0-2.2n. Lundbeck, however, states that its guidance for earnings before interest, taxes, depreciations and amortizations and core EBIT remain unchanged, according to a stock exchange announcement on Friday afternoon.
This comes after the Danish Business Authority having decided that Lundbeck has to have a reassessment of its impairment for 2017. This includes back-tracking a writedown for the drug Rexulti, according to Lundbeck.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Consultant Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Communications Consultant 
Senior Manager, Clinical Trial Budget 
Nordic Medical Affairs Manager 
Key Account Manager, Europe and Asia 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Analytical Coordinator for Analytical Development 
Director Global Engineering 
Chemist for Incoming Materials in QC Department 
(Senior) Drug Substance Specialist 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Quality System Manager 
Client Talent Acquisition Specialist 
Account Manager 
Vice President, Test & Characterisation